We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
15.00 | 0.92% | 1,651.00 | 1,650.50 | 1,651.00 | 1,655.00 | 1,635.00 | 1,642.00 | 920,600 | 10:25:23 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 13.72 | 67.62B |
Date | Subject | Author | Discuss |
---|---|---|---|
08/1/2018 10:02 | Good - "UK pushes to stay in EU medicines agency. Call to still be under bloc’s regulation follows chemical and aviation sectors". | alphorn | |
08/1/2018 02:42 | First technical target 1460p, followed by 1550p | ny boy | |
07/1/2018 22:17 | I think buywell believes he can tip you a share that is at the forefront of a cure for mad cow disease....... mad cow. | prambigear | |
07/1/2018 20:30 | buywell3 What on earth is your motive for spreading this sort of stuff? We live in an age of Publish or Perish and no end of junk is published that is not worth the paper it is printed on, merely offerings from often sub-standard schools to foster their post-grad programs. Fortunately most qualified people, what used to be called doctors, are able to sort between these publications and come up with a reasonable assessment. Please acquit yourself with some sort of medical qualification before propagating this sort of material - an expert denier no doubt. | mayers | |
05/1/2018 20:21 | My prediction over 1400p next week.Pay day Thursday, reinvest back into GSK. | montyhedge | |
05/1/2018 18:33 | Still only just outperforming the FTSE 100 since the rebound. I bought at 1279.5 on 7 December up 6.2%. Ftse 100 7724/ 7320 over the same month or 5.5%. So mostly the general bull. Done a lot better than Aviva and Imperial Brands I bought at the same time mind you. Also wrongly backed those with more cash than Gsk. | stewart64 | |
05/1/2018 18:24 | Wow! Up she goes! 1400 by end Jan at this rate!! | eisler | |
05/1/2018 16:08 | Happy holding added more recently, recovery prospects and an attractive yield, definitely a keeper in the portfolio. | ny boy | |
05/1/2018 09:37 | Apart from tax cuts, which for me makes the dividend safe.Analyst think FTSE 100 to hit 8000, that's must be worth 75p on GSK price surely. | montyhedge | |
05/1/2018 09:27 | 1450p looks a given next few months. US tax cut it's help, 40% of revenue in US. | montyhedge | |
04/1/2018 13:30 | With the US tax cuts, going to be helpful to GSK. 40% of revenue in US. | montyhedge | |
04/1/2018 13:21 | Dividend pay date next Thursday, yippee. | montyhedge | |
04/1/2018 13:20 | It can’t be reasoned with. .... And it absolutely will not stop, ever.... | scotches | |
04/1/2018 10:03 | Monty I think you made that point yesterday and the day before. Repeating yourself all the time is the reason that people are annoyed by you. | daveofdevon | |
04/1/2018 08:59 | Looking for 18.77% return on GSK for 2018, 6% of that dividend.Paid every 13 weeks, superb. US tax cuts to me make the dividend safe. | montyhedge | |
03/1/2018 17:30 | tks tim i must be going blind or stupid or both | billionaire1 | |
03/1/2018 17:07 | billionaire Its in the header. Or add to your monitor NYSE:GSK | tim 3 | |
03/1/2018 16:54 | Currently down a little. | gbh2 | |
03/1/2018 16:45 | anybody know how glaxo is trading in the u s today | billionaire1 | |
03/1/2018 16:45 | anybody know how glaxo is trading in the u s today | billionaire1 | |
03/1/2018 14:52 | Nearly back to breakeven ;) nice. | tim 3 | |
03/1/2018 14:43 | Yes a lot of shareholders will re-invest on the 11th Jan. | montyhedge |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions